Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Teva Pharma adds women's health portfolio with acquisition of Theramex

Jan. 10, 2011

Xoma reports interim phase II data on XOMA-052 in type 2 diabetes

Jan. 10, 2011

Vitae Pharmaceuticals describes novel 11-beta-HSD1 inhibitors

Jan. 10, 2011

Santarus and Depomed resume Glumetza distribution in U.S.

Jan. 7, 2011

Insulin PharmFilm is tested in primates

Jan. 7, 2011

New antagonists of melanin-concentrating hormone MCH1 receptor claimed

Jan. 7, 2011

Wyeth patents new 11-beta-HSD1 inhibitors

Jan. 5, 2011

Takeda discloses new agonists of free fatty acid FFA1 receptor

Jan. 5, 2011

Repros Therapeutics receives approval for phase IIb Androxal trial

Jan. 4, 2011

New antagonists of melanin-concentrating hormone MCH1 receptor identified

Jan. 4, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...